News

IntroductionThe Global Plasmid DNA Manufacturing Market is poised for significant growth, with a valuation of USD 2.13 ...
Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 ...
Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, 'P134 Cell Injection,' which has received Investigational New Drug (IND) ...
Plasmid vectors pET11a-link-NGFP and pMRBAD ... before plating on kanamycin-containing media. Purify the vector products by electrophoresis through 0.8–1% agarose and determine the concentration ...
The expression plasmid pPICZα-AFowlTα1 was linearized with Sac I enzyme following electroporation manufacturer’s instructions. The blank pPICZα-A expression vector was inserted into P. pastoris SMD ...
Addgene is thrilled to have the expertise of this group of leaders in life sciences and technology as part of our management team and Board of Directors – a testament to the value of our vision for a ...
The CRISPR gene editing technology has revolutionized the field of molecular biology, offering unprecedented precision and efficiency in genetic manipulation. With its vast potential in various ...
Market Overview: The European CRISPR gene editing market has experienced significant expansion, driven by advancements in biotechnology and increasing investment in genetic research. With a compound ...
Southern RNA is an Australian CDMO specialising in producing nucleic acid products that support the clinical development of ...
DFA US Vector Equity Fund earns a High Process Pillar rating. The leading factor in the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New ...